Lipoxygenase (LOX) Pathway: A Promising Target to Combat Cancer

(E-pub Ahead of Print)

Author(s): Vishnupriya P, Aparna A, Vijaya Padma V*

Journal Name: Current Pharmaceutical Design

Become EABM
Become Reviewer
Call for Editor


Leukotrienes are one of the major eicosanoid lipid mediators being produced as a result of oxidative transformation of arachidonic acid. Subsequently, they get converted into various cellular signaling hormones by a series of enzymes of myeloid origin to mediateor debilitate inflammation. Interestingly, the available literature demonstrates the pivotal role of eicosanoids in neurodegenerative, obesity, diabetes, cardiovascular diseases and cancers as well. The aberrant metabolism of arachidonic acid by LOX pathway is a common feature of epithelial derived malignancies and suggests the contributory role of dietary fats in carcinogenesis. The enzymes and receptors of the LOX pathway play a significant role in cell proliferation, differentiation and regulation of apoptosis through multiple signaling pathways and have been reported to be involved in various cancers including prostate, colon, lung and pancreatic cancers. So far, leukotriene receptor antagonists and 5-LOX inhibitors have reached up to the clinical trials for treating various diseases. Keeping its various roles in cancer, the review highlights the components of the leukotriene synthesizing machinery, emerging opportunities for pharmacological intervention, and the probability of considering lipoxygenases and leukotriene receptors as good candidates for clinical chemoprevention studies.

Keywords: Eicosanoid, arachidonic acid, leukotrienes, lipoxygenases, cancer, lipoxygenase inhibitors, leukotriene hydroxylase, cysteinyl leukotriene receptor, phytochemicals

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1381612826666210101153216
Price: $95

Article Metrics

PDF: 223